Lyell Immunopharma (NASDAQ:LYEL) Major Shareholder Purchases 2,321,262 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) major shareholder Arch Venture Partners Ix, Llc acquired 2,321,262 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was bought at an average price of $10.77 per share, with a total value of $24,999,991.74. Following the purchase, the insider directly owned 3,747,790 shares of the company’s stock, valued at $40,363,698.30. This represents a 162.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Lyell Immunopharma Price Performance

Shares of LYEL traded down $0.43 during midday trading on Thursday, reaching $15.00. 657,433 shares of the stock were exchanged, compared to its average volume of 139,964. The business’s 50-day moving average price is $10.85 and its 200 day moving average price is $16.73. Lyell Immunopharma, Inc. has a twelve month low of $7.20 and a twelve month high of $45.00. The company has a market capitalization of $367.50 million, a price-to-earnings ratio of -1.17 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, November 4th. The company reported ($1.86) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.20. The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. As a group, equities research analysts expect that Lyell Immunopharma, Inc. will post -7.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in Lyell Immunopharma by 4.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,824 shares of the company’s stock worth $158,000 after buying an additional 679 shares during the last quarter. Opaleye Management Inc. lifted its stake in shares of Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after acquiring an additional 264,928 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Lyell Immunopharma by 119.4% in the 2nd quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock worth $595,000 after acquiring an additional 23,028 shares during the period. Velan Capital Investment Management LP boosted its holdings in shares of Lyell Immunopharma by 2.9% in the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after acquiring an additional 3,000 shares in the last quarter. Finally, venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma in the second quarter valued at about $4,744,643. 66.05% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Lyell Immunopharma

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Updated ronde-cel results showed high response rates in patients with relapsed or refractory large B-cell lymphoma: in the pivotal 3L+ trial, the overall response rate was 91% and the complete response rate was 77%; results in the 2L cohort were 95% and 76%, respectively. Severe cytokine release syndrome was not observed in either group. The data will be presented at the ASH meeting and support interest in the therapy’s potential. Article: Positive updated ronde-cel data
• Positive Sentiment: Lyell secured an approximately $80 million private placement to fund ronde-cel development toward a planned biologics license application (BLA). Needham also gave the shares a “Buy” rating, while a Seeking Alpha article cited the clinical progress and financing in an upgrade to “Buy.” Article: $80 million private placement Article: Needham Buy rating Article: Seeking Alpha upgrade
• Neutral Sentiment: Third-quarter loss per share was $1.86, narrower than analysts’ expected $2.06 loss, but revenue was zero. The earnings beat is modestly favorable, though the results underscore Lyell’s pre-commercial stage and ongoing losses. Article: Third-quarter results
• Negative Sentiment: The private placement involves selling common stock, which can dilute existing shareholders. Investors will also be weighing clinical promise against the remaining development and regulatory risks before ronde-cel can reach the market.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, October 15th. Stifel Nicolaus initiated coverage on shares of Lyell Immunopharma in a report on Thursday, August 6th. They issued a “buy” rating and a $36.00 target price on the stock. Royal Bank Of Canada set a $34.00 price target on shares of Lyell Immunopharma in a research report on Friday, August 14th. HC Wainwright reiterated a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. Finally, Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.86.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.